Consensus on MRD in AML?

Research output: Contribution to journalComment/debatepeer-review

24 Scopus citations


The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.

Original languageEnglish (US)
Pages (from-to)1265-1266
Number of pages2
Issue number12
StatePublished - Mar 22 2018

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Consensus on MRD in AML?'. Together they form a unique fingerprint.

Cite this